- 34
- Episodes
- 16
- Ratings
- Monthly
- Cadence
- 2022
- First episode
About Beyond the Bolus
Brought to you by the makers of Omnipod, Beyond the Bolus explores topics beyond the basics of diabetes management and takes a closer look at the treatment and care of diabetes through the unique perspectives and great minds of people within the diabetes community. Hosted by Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE, this dynamic duo brings forth their passion for serving patients with diabetes and their curiosity to learn to the series. The episodes will include conversations on visions for the future of diabetes care and technology, practical tips for building a care team, compelling clinical data and more!
- Publisher
- Insulet, Maker of Omnipod
- Category
- education · science
- Language
- en
- Explicit
- No
- First episode
- 31 May 2022
- Latest episode
- 13 Oct 2026
Latest episodes
34 episodes in the feed.
13 Oct 2026
The Pharmacy is the Pathway: Dr. Katelyn O'Brien on Simplifying AID Access with Omnipod® 5
This episode welcomes Dr. Katelyn O'Brien, clinical pharmacy specialist, certified diabetes care and education specialist, and the 2026 ADCES Diabetes Care and Education Specialist of the Year, to Beyond the Bolus. Speaking with hosts Dena Gottesman and Nancy Hanna, Dr. O'Brien draws on her nine years at Boston Medical Centre, New England's largest safety-net hospital, to unpack how prescribing Omnipod 5 through the pharmacy channel is reshaping access to automated insulin delivery. Dr. O'Brien walks through why routing through the pharmacy, rather than traditional DME, removes friction for both clinicians and patients: no separate ordering platforms to track, no delays coordinating pump starts, and no gap between when a patient gets their CGM sensor, their insulin, and their Pods. She explains how the trusted, frequent relationship patients already have with their pharmacist, often visited far more often than their primary care team, becomes a built-in layer of support and problem-solving. The conversation also tackles the C-peptide requirement head-on: a Medicare-era policy, not a clinical necessity, that has kept people with type 2 diabetes locked out of AID despite evidence they benefit regardless of insulin deficiency status. Dr. O'Brien explains how going through Medicare Part D removes that barrier entirely and shares a patient story that shows exactly what's at stake when it does. She closes with a call to her fellow PharmDs, especially those embedded in primary care, to see AID as squarely within their scope, not just a type 1 tool, but a way to meet type 2 patients where they already are. Whether you're a pharmacist, a prescribing clinician, or an educator working with underserved populations, this episode makes the case that the shortest path to better outcomes might already be five miles from home. • 04:49 – How pharmacy access removes friction, streamlines prescribing, and helps patients avoid delaysand drop-off in the onboarding process• 08:53 – Pharmacists as trusted diabetes technology advocates• 12:06 – Removing C-Peptide barriers to AID access• 15:06 – Real patient success stories• 18:19 – The future role of pharmacists in expanding AID access How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D). Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life withdiabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.INS-OHS-07-2026-00092 V1.0
9 Sept 2026
Tubeless Trendsetters: The Freedom Factor of Omnipod® 5 with Dr. David Ahn and Justin Eastzer
This month’s episode brings together two voices from different sides of diabetes care: Dr. David Ahn, endocrinologist and Chief of Diabetes Services at Hoag Hospital's Mary and Dick Allen Diabetes Centre in Newport Beach, California, and Justin Eastzer, diabetes advocate known as @diabetech. Together with host Nancy Hanna, they dig into what going tubeless means for the people wearing it and the clinicians prescribing it. Dr. Ahn shares how the absence of tubing helps patients overcome hesitation around starting pump therapy, particularly those concerned about visibility and medical stigma. He discusses the clinical impact of not needing to disconnect for daily activities*, including his personal experience of seeing how this can help reduce rebound hyperglycemia, and he also highlights how the simplicity of Omnipod 5 has been transformative for his older patient population. Justin offers a firsthand patient perspective on how the tubeless form factor gives him freedom across every area of daily life, from workouts to travel, getting dressed, without ever needing to think about where his pump is. The conversation also covers the expanded site rotation options that come with a tubeless system, the convenience of the automated cannula insertion for those with needle phobia, and the latest Omnipod 5 software update featuring the lower 100 mg/dL Target Glucose setting. Dr. Ahn closes with how the free 30-day sample kit†† and single-prescription simplicity help clinicians get hesitant patients started. Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how removing tubing removes barriers to better outcomes. ---------- · 00:00 - Why tubeless matters: reducing stigma and starting AID · 05:06 - The patient perspective: freedom in daily life · 08:57 - Site rotation, waterproof form-factor†, and not needing to disconnect for daily activities* · 11:41 - Automated insertion and simplicity for all ages · 16:50 - Getting patients started with a single prescription for Omnipod 5 ---------- * The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. † Daily normal activities are related to recreational, educational, and occupational activities. The Pod must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment, and the Controller or smartphone should be placed outside of the procedure room. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide. †† Omnipod® 5 Intro Kit 30-Day Trial Terms and Conditions 1. Program Eligibility Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 Intro Kit 30-day trial program (the “Program”) is open to patients who have a valid Omnipod 5 prescription as well as a compatible CGM prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH® or Omnipod Insulin Management System. This offer is not valid for participants whose Omnipod 5 or compatible CGM prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program. Please contact Insulet Customer Support at 1-800-591-3455 for details. 2. Program Details With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following: • A participant shall sign the Omnipod® 5 Intro Kit 30-Day Trial Acknowledgement through the appropriate platform provided by Insulet. • Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners. • IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below. • IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below. • For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods. • Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan. • In order to use the Omnipod 5 System in Automated Mode, the User must also procure a compatible CGM. This program does not include supply of a compatible CGM. Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time. 3. Copay Card Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable 4. Product Dispense Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include: • One (1) Omnipod 5 Controller • Ten (10) Omnipod 5 Pods • One (1) Omnipod 5 User Guide • One (1) Controller charging cable The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit. How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D). Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you. INS-OHS-07-2026-00089V1.0
11 Aug 2026
Settings, Trust, and Time in Range: Optimizing Omnipod® 5 with Dr. Sufyan Hussain
Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data. Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems. The conversation also covers real patient stories, including individuals with significant fear of hypoglycemia and lower health and tech literacy, who saw meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy. Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care. 00:00 - Why real-world evidence (RWE) matters 05:12 - Key real-world insights: Equity, simplicity, and outcomes 08:12 - Optimizing Omnipod 5 settings for improved clinical results 15:24 - Expanding access: Patient success stories and the power of simplicity 1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026. RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL. How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice? Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D). Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective. Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
- Apple Podcasts (US)
- 4.7 / 5
- 14 ratings
- Spotify
- 5.0 / 5
- 2 ratings
Podcast Authority Score: 30 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
- Quality
- 40
- Social presence
- 0
- YouTube
- 0
- Engagement
- 51
Contact Beyond the Bolus
- Guest appearances
- Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Beyond the Bolus?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show
Podcast research with Pod Engine